Search the Newsreel

Why is Abcellera Biologics stock surging today?

Abcellera Biologics (ABCL) stock surged over 30% in pre-open trading after its antibody, ABCL 635, met the primary efficacy endpoint in a Phase 2 clinical trial for menopausal hot flashes, showing an 83% reduction in frequency. This clinical success, combined with strong analyst conviction …

BCE Inc. (BCE) refreshes ethics and conduct Code covering trading, AI and privacy

BCE Inc. has updated its Code of Business Conduct to reinforce ethical and compliance expectations for all directors, executives, and employees, including Canadian subsidiaries. The refreshed Code addresses critical areas such as insider trading, responsible AI use, data privacy, and conflict of interest management. …

AbCellera's ABCL635 Delivers Strong Phase 2 Data; Stock Jumps 33%

(RTTNews) - AbCellera Biologics Inc. (ABCL) announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an investigational NK3R antagonist antibody for moderate-to-severe vasomotor symptoms due to menopause. The study met its primary efficacy endpoints achieving statistically …

AbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial

AbCellera Biologics announced positive top-line results from its Phase II trial of ABCL-635, a non-hormonal treatment for menopausal hot flashes. The study showed an 83% reduction in moderate-to-severe hot flashes, along with improvements in symptom severity and sleep disturbance, and a favorable tolerability profile. …

ABCL Stock Rips As Vertex Deal And Data Catalyst Fire Up Traders

AbCellera Biologics Inc. (ABCL) stock surged over 24% due to strong optimism surrounding its antibody discovery platform, a new collaboration with Vertex Pharmaceuticals, and upcoming Phase 2 data for ABCL635. The Vertex deal provides $28 million upfront, with potential milestones and royalties, validating ABCL's …

Weekly Recap: Q2 adjusted EPS and Bell CTS revenue rise from Ziply Fiber

BCE Inc. (NYSE:BCE) reported Q2 adjusted EPS of C$0.65 and revenue of C$6.18 billion, with net income at C$558 million. Bell CTS's operating revenue increased by 0.4% to C$5.36 billion, largely due to the acquisition of Ziply Fiber, which helped offset weaker Canadian results. …

AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Just Slashed This Year's Revenue Estimates By 22%

Analysts have significantly revised down AbCellera Biologics Inc.'s (NASDAQ:ABCL) revenue estimates for 2026 by 22%, now forecasting US$25 million, which represents a 62% decline year-over-year. Despite this pessimistic outlook, the company's share price has recently risen by 19%. The updated forecasts suggest AbCellera Biologics …

AbCellera To Present Phase 2 Results Of ABCL635 For Menopause Symptoms Today

(RTTNews) - AbCellera Biologics Inc. (ABCL) announced that it will release top-line results from its Phase 2 clinical trial from its Phase 2 clinical trial of ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes due to menopause, before …

How (BCE) Movements Inform Risk Allocation Models

This article analyzes Bce Inc. (NYSE: BCE) using AI models, highlighting a strong near-term sentiment that could influence neutral mid and long-term outlooks. It details three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each with specific entry zones, targets, and stop losses. The …

AbCellera Biologics (ABCL) Is Up 21.4% After First Phase 2 Readout For Novel NK3R Antibody – Has The Bull Case Changed?

AbCellera Biologics (ABCL) saw its stock rise 21.4% following the first Phase 2 readout for its novel NK3R antibody, ABCL635, targeting menopausal vasomotor symptoms. This marks a significant step in AbCellera's shift towards developing internal therapeutic programs, offering an early test of its new …

BCE Inc. 2026 Q2 - Results - Earnings Call Presentation (TSX:BCE:CA) 2026-08-08

BCE Inc. has published its Q2 2026 earnings call presentation. The company reported an EPS of $0.65, missing estimates by $0.05, and revenue of $6.18 billion, a 1.50% year-over-year increase but missing estimates by $1.09 million. The slide deck was released in conjunction with …

AbCellera (NASDAQ:ABCL) Shares Surge Ahead of Monday's ABCL635 Phase 2 Trial Results

AbCellera's shares surged ahead of the release of its ABCL635 Phase 2 trial results on Monday, with the stock gaining 9.7% in after-hours trading, adding an estimated $205 million to its market value. Despite recent quarterly revenue declines, the anticipation of clinical validation for …

BCE Inc. (TSE:BCE) Given Consensus Rating of "Moderate Buy" by Brokerages

BCE Inc. (TSE:BCE) has received a "Moderate Buy" consensus rating from 13 analysts, with an average 12-month price target of C$37.31. The company recently reported quarterly revenue of C$6.18 billion and earnings of C$0.65 per share, and declared a quarterly dividend of $0.4375, offering …

BCE Inc. Is Maintained at Sector Outperform by Scotia

Scotia has maintained its "Sector Outperform" rating for BCE Inc. This indicates that the analyst firm believes BCE will perform better than the overall sector.

AbCellera Biologics | 8-K: Current report

This document is an 8-K current report filed by AbCellera Biologics. The content of the report itself is not provided, only the fact that it is an 8-K filing.

BCE’s AI Data Centre Push and Record Fiber Adds Might Change The Case For Investing In BCE (TSX:BCE)

BCE Inc. reported past Q2 2026 results showing operating revenue of CA$6,176 million, modestly higher than a year earlier, while net income and earnings per share from continuing operations eased slightly year-on-year. Alongside the earnings, BCE affirmed a quarterly dividend, highlighted record fiber and …

BCE Inc. stock falls Friday, underperforms market

BCE Inc. (BCE) stock fell by 0.63% on Friday, closing at C$31.67, underperforming the broader Canadian market. This decline occurred despite the S&P/TSX Composite Index rising by 0.68%. The company's stock is now 12.6% below its 52-week high of C$36.25, reached on March 17th.

BCE's Q2 Earnings Beat Estimates on Ziply Fiber & Media Momentum

BCE Inc. BCE reported second-quarter 2026 adjusted earnings of C$0.65 per share (47 cents), up 3.2% year over year. The figure beat the Zacks Consensus Estimate by 2.2%. Total operating revenues rose 1.5% to C$6.18 billion ($4.461 billion), topping the consensus estimate of $4.401 …

World Cup audience, ad demand helps buoy Bell Media revenues in Q2

Bell Media's revenues in Q2 were significantly boosted by record audiences and strong advertiser demand during the FIFA World Cup. Despite an overall lower profit for parent company BCE Inc., Bell Media's operating revenue increased by 8.9% to C$918M, with ad revenue up 5.3% …

Dimensional Fund Advisors LP Has $22.21 Million Stake in BCE, Inc. $BCE

Dimensional Fund Advisors LP significantly increased its stake in BCE, Inc. by 118.6% in the first quarter, now owning 879,778 shares valued at $22.21 million. Other institutional investors like Massachusetts Financial Services Co. MA, Intact Investment Management Inc., and Vanguard Group Inc. also raised …

Bank of America Corp DE Has $122.10 Million Stake in BCE, Inc. $BCE

Bank of America Corp DE increased its stake in BCE, Inc. by 6.2% in the first quarter, now holding 4.84 million shares valued at approximately $122.1 million. This makes Bank of America a significant institutional investor in BCE, which saw its second-quarter adjusted EPS …

AbCellera Biologics (ABCL) Stock Jumps As Cash Burn Fuels Pipeline Debate

AbCellera Biologics (ABCL) saw its stock jump 10.3% despite reporting a significant cash burn and widening net loss in Q2 2026. The market reaction is attributed to the company's substantial cash pile of US$567 million and over US$675 million in liquidity, which is being …

AbCellera Biologics Inc. $ABCL Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC significantly reduced its stake in AbCellera Biologics Inc. (NASDAQ:ABCL) by 36.8% in the first quarter, selling 878,600 shares but still retaining 1.51 million shares valued at $5.27 million. This comes as AbCellera reported weaker-than-expected quarterly results, missing both earnings per share …

EDGAR Filing Documents for 0000718940-26-000009

This SEC EDGAR filing details the Form 6-K submitted by BCE INC. for its second fiscal quarter of 2026, ending June 30, 2026. The filing includes the company's Management's Discussion and Analysis, financial statements, CEO/CFO certifications, and a news release. It also contains various …

BCE Inc (BCE) (Q2 2026) Earnings Call Highlights: AI Fabric Momentum and Fiber Growth Drive ...

This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Consolidated revenue increased 1.5% and adjusted EBITDA grew 1%, with over $1 billion in free …

BCE Inc (BCE) (Q2 2026) Earnings Call Highlights: AI Fabric Momentum and Fiber Growth Drive ... By GuruFocus

BCE Inc. reported Q2 2026 earnings with positive points including increased revenue, improved postpaid wireless churn, and strong fiber growth. The company also highlighted significant momentum in its Bell AI Fabric, with 335 MW contracted capacity and construction on track for new facilities. Despite …

AbCellera Biologics Inc. Stock 12‑Month Price Target Raised to $10.75, Implies 82% Upside

AbCellera Biologics Inc. (ABCL) has seen its average 12-month price target raised to $10.75 by 8 analysts, up from $10.50, with individual forecasts ranging from $7 to $13. This updated target suggests an 82% potential upside based on the August 5th closing price. The …

BCE (BCE) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended June 2026, BCE (BCE) reported revenue of $4.46 billion, up 1.5% over the same period last year. EPS came in at $0.47, compared to $0.46 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $4.4 …

BCE (BCE) Q2 Earnings and Revenues Top Estimates

BCE (BCE) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.46 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

BCE Inc Backs 2026 Adj EPS View of Down 5%-11% >BCE.T

BCE Inc. has reaffirmed its adjusted earnings per share (EPS) outlook for 2026, anticipating a decline of 5% to 11%. This statement reflects the company's financial projections and market expectations for its future performance.

Earnings call transcript: AbCellera misses Q2 2026 estimates as revenue drops

AbCellera Biologics Inc. reported a wider-than-expected Q2 2026 loss and revenue significantly below analyst estimates, with revenue dropping by 76% year-over-year. The company attributed the revenue decline to a strategic shift from external collaborations to internal drug development, leading to increased R&D spending. Despite …

Earnings Flash (BCE.TO) BCE Inc. Posts Q2 Adjusted EPS C$0.65 vs. FactSet Est of C$0.64

BCE Inc. (BCE.TO) reported its Q2 adjusted Earnings Per Share (EPS) of C$0.65, surpassing FactSet's estimate of C$0.64. The company also saw an increase in Q2 adjusted earnings and operating revenue, reaffirming its 2026 guidance and maintaining a higher capital expenditure plan for the …

AbCellera Biologics Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ABCL) 2026-08-06

This document is AbCellera Biologics' 10-Q filing for its Q2 2026 earnings report. A 10-Q is a comprehensive quarterly report filed by public companies with the SEC, containing unaudited financial performance. It provides a detailed overview of the company's financial condition and results of …

Stifel Nicolaus Issues Positive Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price

AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ...

This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AbCellera Biologics Inc (NASDAQ:ABCL) completed enrollment for the phase 2 study of ABCL-635 in treating …

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items. This …